Robeco Institutional Asset Management B.V. Acquires 15,815 Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Robeco Institutional Asset Management B.V. boosted its holdings in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 25.3% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 78,273 shares of the biopharmaceutical company’s stock after purchasing an additional 15,815 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Alexion Pharmaceuticals were worth $10,250,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of ALXN. Livforsakringsbolaget Skandia Omsesidigt raised its stake in shares of Alexion Pharmaceuticals by 30.4% during the second quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 2,572 shares of the biopharmaceutical company’s stock valued at $337,000 after acquiring an additional 600 shares during the last quarter. Vigilant Capital Management LLC raised its stake in shares of Alexion Pharmaceuticals by 4.1% during the second quarter. Vigilant Capital Management LLC now owns 113,829 shares of the biopharmaceutical company’s stock valued at $14,909,000 after acquiring an additional 4,467 shares during the last quarter. Bank of The West raised its stake in shares of Alexion Pharmaceuticals by 4.1% during the second quarter. Bank of The West now owns 34,841 shares of the biopharmaceutical company’s stock valued at $4,563,000 after acquiring an additional 1,384 shares during the last quarter. Oakbrook Investments LLC bought a new position in shares of Alexion Pharmaceuticals during the second quarter valued at about $1,601,000. Finally, Fox Run Management L.L.C. bought a new position in shares of Alexion Pharmaceuticals during the second quarter valued at about $604,000. 94.75% of the stock is owned by institutional investors and hedge funds.

ALXN has been the subject of a number of research reports. TheStreet raised shares of Alexion Pharmaceuticals from a “c” rating to a “b” rating in a research note on Thursday, April 25th. JPMorgan Chase & Co. initiated coverage on shares of Alexion Pharmaceuticals in a research note on Wednesday, July 31st. They issued an “overweight” rating and a $172.00 price target for the company. Citigroup decreased their price target on shares of Alexion Pharmaceuticals from $180.00 to $165.00 and set a “buy” rating for the company in a research note on Thursday, May 23rd. BidaskClub downgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, July 31st. Finally, Zacks Investment Research downgraded shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, May 24th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and twelve have given a buy rating to the company’s stock. Alexion Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $162.88.

ALXN stock traded down $3.77 during trading on Monday, reaching $108.57. The company had a trading volume of 29,490 shares, compared to its average volume of 2,116,750. Alexion Pharmaceuticals, Inc. has a 52 week low of $92.56 and a 52 week high of $141.86. The stock has a market cap of $25.19 billion, a P/E ratio of 15.43, a P/E/G ratio of 1.07 and a beta of 1.65. The business’s 50 day moving average price is $123.52. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.56 and a current ratio of 4.04.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Wednesday, July 24th. The biopharmaceutical company reported $2.64 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.13 by $0.51. The company had revenue of $1.20 billion during the quarter, compared to the consensus estimate of $1.18 billion. Alexion Pharmaceuticals had a net margin of 29.64% and a return on equity of 20.23%. Alexion Pharmaceuticals’s revenue was up 15.1% on a year-over-year basis. During the same period in the prior year, the firm earned $2.07 earnings per share. Analysts forecast that Alexion Pharmaceuticals, Inc. will post 9 earnings per share for the current year.

In other Alexion Pharmaceuticals news, insider Aradhana Sarin sold 578 shares of the company’s stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $132.00, for a total value of $76,296.00. Following the sale, the insider now owns 30,201 shares in the company, valued at $3,986,532. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Indrani Lall Franchini sold 4,500 shares of the company’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $132.78, for a total transaction of $597,510.00. Following the completion of the sale, the executive vice president now owns 29,627 shares in the company, valued at approximately $3,933,873.06. The disclosure for this sale can be found here. In the last 90 days, insiders sold 428,567 shares of company stock worth $53,420,869. Corporate insiders own 4.08% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Recommended Story: What is meant by buying and selling pressure?

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.